The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001067369p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
28/07/2026
Date registered
Help: Date registered
28/08/2026
Date last updated
Help: Date last updated
28/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
28/08/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Effectiveness of the Virtual or In-person Physiotherapist-led Evaluation of Referrals to spine surgeons (VIPER) model of care: a randomised controlled trial
Scientific title
Effectiveness of the Virtual or In-person Physiotherapist-led Evaluation of Referrals to spine surgeons (VIPER) model of care: a randomised controlled trial.
Additional trial identifiers [1] 318033 0
Nil
Universal Trial Number (UTN)
Trial acronym
VIPER Trial
Related trial records

Health condition
Health condition(s) studied:
non-specific low back pain 343044 0
Condition category
Condition code
Musculoskeletal 339140 339140 0 0
Other muscular and skeletal disorders
Public Health 339286 339286 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will receive a comprehensive initial assessment conducted by the VIPER physiotherapist via videoconference or in person (based on patient preference or clinician need such as to conduct a neurological exam in person) which involves taking a thorough patient history, performing a thorough subjective and objective assessment of participants’ condition, and reviewing any imaging reports and previous healthcare use for their condition. Following this assessment, the VIPER physiotherapist will triage participants as needing either non-surgical care or an appointment with a surgeon guided by the NSW Agency for Clinical Innovation (ACI)’s 2024 audit indicators for spine surgery. Following the initial assessment and triage decision, the VIPER physiotherapist will inform the relevant spine surgeon about their assessment and triage decisions and provide concise regular updates to the surgeon about participant progress during their episode of care. The VIPER physiotherapist will seek surgeon’s input when unsure about their initial triage decision or management.

If the VIPER physiotherapist deems a participant suitable for non-surgical care, participants will be booked for a course of in-person or telehealth physiotherapy and/or referred to other health professionals as required. Physiotherapy management will be guided by the principles recommended in the 2022 Australian Commission on Safety and Quality in Health Care Low Back Pain Clinical Care Standard and the 2023 World Health Organisation Guidelines on Chronic Low Back Pain. The VIPER physiotherapist may choose to refer to other health professionals (e.g. rheumatologist, psychologist) and act in a care coordination capacity if they identify that participants’ have treatment needs beyond the scope of physiotherapy care (e.g., require comprehensive medication review, psychosocial support, diet and weight loss advice). Participants deemed suitable for non-surgical care will be discharged from the hospital if they no longer need to see a surgeon or return to the wait list to see the surgeon for an initial surgical opinion if they are not responding to treatment, based on shared decision making between the participant and the physiotherapist. If the VIPER physiotherapist initially deems a participant as needing to see a surgeon, they will join the wait list for the next available appointment (as per participants in the control group). The VIPER physiotherapist will also notify the surgeon if they identify that participants need an in-person appointment with the surgeon more urgently (e.g., due to progressive neurological signs or symptoms missed on the referral).
The initial assessment would usually be a 1 hour appointment. Some examples of what physiotherapy management will be administered are advice, exercise prescription, home exercise program. The treatment recording forms have a list if you need more information. We have suggested the a course of physiotherapy could be trialled for up to 6 months but the frequency and duration of appointments will be at the discretion of the VIPER physiotherapist.
Intervention fidelity will be based on:
- participants receiving an initial physiotherapy assessment; and
- participants being recommended care or given referrals that align with the VIPER physiotherapists triage decision (e.g., physiotherapy care, referral to other healthcare professionals, remain on current trajectory with surgical services).

Assessment recording forms will be used to evaluate assessment and initial triage decision, and treatment recording forms will be used to evaluate fidelity and assess if treatment provided was guideline-based.

Consistency across sites will be maintained via audits of practice during recruitment to ensure fidelity is of a high standard. For example, fidelity will be assessed for the first 3 patients at each site in the VIPER arm. Following this, random spot checks will be used to monitor fidelity. The VIPER research team will be available to answer any questions from the VIPER physiotherapist about the trial process and forms to be completed.



The study duration is one year for each participant.
Intervention code [1] 334912 0
Treatment: Other
Description of the comparator or control
Participants in the control group will join the usual waiting list for an in-person appointment with a surgeon. Participants may still receive care from other healthcare services (e.g. GP care and associated imaging, medication, pain management or private physiotherapy). Trial data are collected per schedule of assessments.
Control group
Active

Outcomes
Primary outcome [1] 346379 0
Disability at 6 months
Timepoint [1] 346379 0
At Baseline and 6 months post- randomisation .
Secondary outcome [1] 465573 0
Patient- reported outcome - Quality of life
Timepoint [1] 465573 0
At baseline, 3, 6 and 12- months post- randomisation
Secondary outcome [2] 465574 0
Satisfaction with care
Timepoint [2] 465574 0
At 3, 6 and 12- months post- randomisation
Secondary outcome [3] 465575 0
Healthcare and medication use (This is a composite outcome)
Timepoint [3] 465575 0
At baseline, 3, 6 and 12- months post- randomisation
Secondary outcome [4] 465576 0
Reassurance activity is safe (mediator outcome)
Timepoint [4] 465576 0
At 4- week post- randomisation
Secondary outcome [5] 465577 0
Reassurance of a good prognosis (mediator outcome)
Timepoint [5] 465577 0
At 4- week post- randomisation
Secondary outcome [6] 465578 0
Reassurance there is management options (mediator outcome)
Timepoint [6] 465578 0
At 4- week post- randomisation
Secondary outcome [7] 465579 0
Anxiety and depression (mediator outcome, this will be assessed as a composite outcome)
Timepoint [7] 465579 0
At baseline and 4- week post- randomisation
Secondary outcome [8] 465580 0
Pain self-efficacy
Timepoint [8] 465580 0
At 4 weeks post randomisation
Secondary outcome [9] 465581 0
Reassurance condition is not serious
Timepoint [9] 465581 0
At 4 weeks post-randomisation
Secondary outcome [10] 465582 0
Recovery expectations
Timepoint [10] 465582 0
At 4- week post- randomisation
Secondary outcome [11] 465583 0
Fear of movement
Timepoint [11] 465583 0
At 4 weeks post randomisation.

Eligibility
Key inclusion criteria
Adult patient (18 years or greater) with non-specific low back pain and/or lumbar spine-related leg pain (e.g. radicular pain, lumbar radiculopathy with leg pain, leg pain due to lumbar spinal stenosis) and new referral (defined as being referred within the last 6 weeks) to a public hospital spine surgeon which is considered ‘non- urgent’ by the surgery clinic and willing to participate and provide follow-up data and able to understand spoken and written English to provide sufficient informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Suspected serious underlying pathology (e.g., malignancy, fracture, infection) or New referral requiring urgent appointment with a surgeon (e.g. rapidly progressive radiculopathy or upper motor neuron lesion).

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Eligible and consenting participants will be randomly allocated (ratio 1:1) to either the intervention group, Virtual or In-person Physiotherapist-led Evaluation of Referrals to spine surgeons (VIPER) model of care or usual care (i.e. joining the waiting list for an in-person appointment with a surgeon). Randomisation will be at the patient-level.

The 1:1 random allocation sequence will be independently generated by a biostatistician using randomly permuted blocks of variable size (2 and 4) to help ensure equal numbers in both groups and concealed allocation. Stratification variables for the randomisation sequence include study sites and the presence of lumbar-spine related leg pain. The random allocation sequence will be uploaded in the REDCap study database to allow the randomisation to be performed online by the VIPER physiotherapist after baseline data have been entered. The allocation schedule will be concealed from potential participants and from all on-site staff associated with the trial. The VIPER physiotherapist will randomise all eligible participants using the REDCap system.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Eligible and consenting participants will be randomly allocated (ratio 1:1) to either the intervention group, Virtual or In-person Physiotherapist-led Evaluation of Referrals to spine surgeons (VIPER) model of care or usual care (i.e. joining the waiting list for an in-person appointment with a surgeon). Randomisation will be at the patient-level.

The 1:1 random allocation sequence will be independently generated by a biostatistician, using randomly permuted blocks of variable size (2 and 4) to help ensure equal numbers in both groups and concealed allocation. Stratification variables for the randomisation sequence include study sites and the presence of lumbar-spine related leg pain. The random allocation sequence will be uploaded in the REDCap study database to allow the randomisation to be performed online by the VIPER physiotherapist after baseline data have been entered. The allocation schedule will be concealed from potential participants and from all on-site staff associated with the trial. The VIPER physiotherapist will randomise all eligible participants using the REDCap system.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
A sample size of 314 participants (157 per group) provides 90% power to detect a difference between groups of 10 points on the ODI at 6 months post-randomisation (primary endpoint). The minimal clinically important difference (MCID) for the Oswestry Disability Index in lumbar spine surgery populations varies substantially. A between-group difference of 10 represents a conservative estimate of the Minimal Clinically Important Difference (MCID) for the ODI across diverse types of lumbar spine conditions (e.g., non-specific low back pain, lumbar-spine related leg pain) and is a conservative estimate against between-group effects that large, high-quality lumbar spine trials in a surgical population have been powered to detect.

We assumed a conservative standard deviation of 25 (2 points larger than the largest SD reported across several large, high-quality lumbar spine trials in a surgical population), a two-tailed alpha of 5%, and a conservative 15% loss to follow-up. This sample size will allow our trial to be large enough to provide a definitive answer about the effectiveness of VIPER. It is also feasible within our recruitment time frame based on feedback from department heads involved in VIPER’s co-design and given the number of referrals to spine surgery clinics from our partner sites (e.g., Concord Hospital: >400 referrals per year; Prince of Wales: >520 referrals per year; John Hunter: >520 referrals per year; Royal North Shore: >240 per year; Westmead: >240 per year); assuming 50% of referrals are ‘non-urgent’ and a conservative 40% consent rate from our team’s waiting list trials.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 29919 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [2] 29920 0
Concord Repatriation Hospital - Concord
Recruitment hospital [3] 29921 0
John Hunter Hospital - New Lambton
Recruitment hospital [4] 29922 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 46280 0
2065 - St Leonards
Recruitment postcode(s) [2] 46281 0
2139 - Concord
Recruitment postcode(s) [3] 46282 0
2305 - New Lambton
Recruitment postcode(s) [4] 46283 0
2145 - Westmead

Funding & Sponsors
Funding source category [1] 322591 0
Government body
Name [1] 322591 0
Australian Department of Health, Disability and Ageing
Country [1] 322591 0
Australia
Funding source category [2] 322593 0
Charities/Societies/Foundations
Name [2] 322593 0
HCF Health Services Research Grant
Country [2] 322593 0
Australia
Primary sponsor type
University
Name
The University of Sydney
Address
Country
Australia
Secondary sponsor category [1] 325512 0
None
Name [1] 325512 0
Address [1] 325512 0
Country [1] 325512 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 321057 0
Sydney Local Health District HREC – Concord Repatriation General Hospital
Ethics committee address [1] 321057 0
Ethics committee country [1] 321057 0
Australia
Date submitted for ethics approval [1] 321057 0
05/05/2026
Approval date [1] 321057 0
Ethics approval number [1] 321057 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152518 0
Dr Andrew Gamble
Address 152518 0
The Institute for Musculoskeletal Health, 77-79 Parramatta Road, Camperdown, NSW 2050
Country 152518 0
Australia
Phone 152518 0
+61 0400464181
Fax 152518 0
Email 152518 0
Contact person for public queries
Name 152519 0
Andrew Gamble
Address 152519 0
The Institute for Musculoskeletal Health, 77-79 Parramatta Road, Camperdown, NSW 2050
Country 152519 0
Australia
Phone 152519 0
+61 0400464181
Fax 152519 0
Email 152519 0
Contact person for scientific queries
Name 152520 0
Andrew Gamble
Address 152520 0
The Institute for Musculoskeletal Health, 77-79 Parramatta Road, Camperdown, NSW 2050
Country 152520 0
Australia
Phone 152520 0
+61 0400464181
Fax 152520 0
Email 152520 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.